anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a composition processed with wine and health care wine for treating hyperlipoidemia, and a preparation method and an application of the health care wine. The composition comprises the following components in parts by weight: 25-45parts of wall-broken pine pollen, 25-40 parts of hawthorn fruit, 20-40 parts of kudzuvine root, 15-30 parts of cassia seed and 5-15 parts of liquoric root. The health care wine is prepared by adopting the composition processed with the wine and taking white spirit, yellow wine, rice wine or medical alcohol as a solvent through performing cold dipping, hot dipping, reflux, diacolation and ultrasonic or Soxhlet extraction. The preparation method respectively discloses steps and process parameters of diacolation, ultrasonic treatment, Soxhlet extraction and other methods. The invention further discloses application of the health care wine in the preparation of medicaments for reducing the content of total cholesterol, triglyceride and low-density lipoprotein in blood. Various active ingredients extracted from pine pollen and other medicinal materials can enable the health care wine to have the significant effect of reducing blood fat, and by long-term consumption, the health care wine can prevent, relieve and treat the hyperlipoidemia. The health care wine disclosed by the invention has the characteristics of faint scent, purity, mellow, sweet and soft taste and lasting fragrance after drinking.
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) triggered an unprecedented public health crisis known as the coronavirus disease 2019 (COVID-19) pandemic. Gastrointestinal (GI) symptoms develop in patients during acute infection and persist after recovery from airway distress in a chronic form of the disease (long COVID). A high incidence of irritable bowel syndrome (IBS) manifested by severe abdominal pain and defecation pattern changes is reported in COVID patients. Although COVID is primarily considered a respiratory disease, fecal shedding of SARS-CoV-2 antigens positively correlates with bowel symptoms. Active viral infection in the GI tract was identified by human intestinal organoid studies showing SARS-CoV-2 replication in gut epithelial cells. In this review, we highlight the key findings in post-COVID bowel symptoms and explore possible mechanisms underlying the pathophysiology of the illness. These mechanisms include mucosal inflammation, gut barrier dysfunction, and microbiota dysbiosis during viral infection. Viral shedding through the GI route may be the primary factor causing the alteration of the microbiome ecosystem, particularly the virome. Recent evidence in experimental models suggested that microbiome dysbiosis could be further aggravated by epithelial barrier damage and immune activation. Moreover, altered microbiota composition has been associated with dysregulated serotonin pathways, resulting in intestinal nerve hypersensitivity. These mechanisms may explain the development of post-infectious IBS-like symptoms in long COVID. Understanding how coronavirus infection affects gut pathophysiology, including microbiome changes, would benefit the therapeutic advancement for managing post-infectious bowel symptoms.
PURPOSE:To obtain a whitening agent, containing lactic acids selected from lactic acid, alkaline earth metal lactates and nonmetallic compounds of the lactic acid in a specific concentration and capable of suppressing melanization and useful for preventing and treating pigmentation, such as liver-spot and sunburn. CONSTITUTION:A whitening agent containing lactic acids selected from lactic acid, alkali metal or alkaline earth metal lactates and nonmetallic compounds of the lactic acid in >=5vol./vol.%, preferably 5.0-50vol./vol.%, especially 8.0-30 vol./vol.% concentration. Furthermore, unsaturated fatty acids are preferably contained therein. Lauroleic acid (C121), myristoleic acid (C141), pentadecenoic acid (C151), etc., can be cited as the unsaturated fatty acids. In use, pH of the lactic acids is 2.5-9.0, preferably 3.0-8.0 and the dose thereof for an adult per day is 0.1-500g. The active ingredient is used alone or physiologically active substances, nutriments, etc., are preferably used therewith in combination.
Patients will receive 3 radiotherapy treatments (one treatment every 3-5 days) during weeks 3 and 4. The first treatment will occur 6 (+/- 2) hours after the Talimogene Laherparepvec administration at week 3.Talimogene Laherparepvec will be administered at weeks 0, 3, 5, 7, 9, 11, 13 and 15. The first dose of Talimogene Laherparepvec will be 10\^6 plaque forming units (PFU)/mL, followed three weeks later by a dose of 10\^8 pfu/mL.
The present invention relates to the field of immunotherapy technology, in particular to adoptive T cell therapy or T Cell Receptor (TCR) gene therapy. The invention provides a nucleic acid encoding at least one TCR alpha or beta chain construct of a TCR construct capable of specifically binding the MYD88L265P peptide of seq id No. 2 in the presence of HLA-B07: 02 having high affinity for said peptide/HLA complex. The invention also provides proteins and host cells corresponding to the above nucleic acids, preferably CD8+ T cells, and the medical use of said nucleic acids, proteins or host cells, in particular in the diagnosis, prevention and/or treatment of cancers expressing MYD88L265P, such as non-hodgkin's B-cell lymphoma selected from diffuse large B-cell lymphoma (DLBCL), e.g. activated B-cell DLBCL (ABC-DLBCL) or primary CNSDLBCL, cutaneous DLBCL, leg DLBCL or testicular DLBCL, lymphoplasmacytic lymphoma (LPL), e.g. Waldenstrom Macroglobulinemia (WM), and IgM monoclonal gammopathy (IgMMGUS).
The solution instilled into the central venous catheter lumens after each HD session and left in the catheter until the next session (catheter locking solution) is used to prevent thrombosis during the period between HD sessions and may also prevent catheter-related infection. However, evidence supporting the use of various locking solutions to achieve these objectives is limited. Heparin has been the traditional locking solution. Several small studies have assessed whether citrate and heparin are equally efficacious for maintaining catheter patency but the interpretation of the results was limited because the studies had a short follow-up period and included both uncuffed and cuffed central venous catheters.

Thrombosis is a major cause of HD catheter dysfunction, and this problem is rectified by the use of thrombolytic agents, invasive procedures for declotting, or catheter replacement. A thrombus at the tip of the catheter or a fibrin sheath around it may resist local thrombolysis if it is not reached by sufficient concentrations of the drug. Urokinase has traditionally been used as the thrombolytic agent for HD vascular access declotting, and success rates for declotting vary from 55% to 85%. However, successful treatment of occluded central venous catheter (non HD) with recombinant tissue plasminogen activator (rt-PA) or alteplase was recently achieved in more than 1,000 patients with success (function restored in 798 patients \[75.0%; 95% CI: 72.3 to 77.6%\]). Serious adverse events monitored within 30 days was very rare and efficacy was independent of age, sex, body weight, and catheter type.
The present invention relates to a preparation method of ginseng green Huajing. The extracts of the traditional green plants are selected, such as ginseng, common yam rhizome, hawthorn fruit, tangerine peel, etc. which invigorate the spleen, lucid ganoderma which invigorates the heart, barbary wolfberry fruit which invigorates the kidney, semen cassiae which invigorates the liver, Chinese caterpillar fungus which invigorates the lung, etc. By combining with the modern traditional Chinese medicinal materials such as sachalin rhodiola rhizome, manyprickle acanto-panax root, etc., the formula is formed according to medical speciality meridian distribution and a complement function. The ginseng green Huajing is prepared by adopting the modern technology of extraction. Because the ginseng green Huajing contains multiple effective components such as ginsenoside, etc., the ginseng green Huajing can improve and enhance the functions of nerve systems, blood circulation systems, blood formation systems, immunity systems, incretion systems, etc. Consequently, the efficiency of improving physique, enhancing the immunizing power and the resistance of the human body, resisting fatigue, resisting aging, etc. can be achieved. The ginseng green Huajing is suitable for persons who have weak constitution, aneuria and senility and serves as a health product for weak persons who are ill and have surgery and parturition.
Participants received vemurafenib, 960 mg, twice daily for 6 weeks (Vem1 Phase). After a washout period of 3-10 days, patients received ipilimumab, 10 mg/kg, every 3 weeks for a maximum of 4 doses. At Week 24, participants received ipilimumab, 10 mg/kg, every 12 weeks until disease progression or unacceptable toxicity. Patients who did not progress or have unacceptable toxicity in the Vem1 Phase were retreated with vemurafenib (Vem 2 Phase) at the last dose level identified at the end of the Vem1 Phase until disease progression or unacceptable toxicity.
Systems and methods for determining billing codes and numbers of billing units for time-based medical services. Each medical service is associated with a service type, a start time, and an end time. Embodiments identify medical services associated with the same service type that overlapped and modifying the start time and/or the end time of at least one of the overlapping medical services so that they no longer overlap. A hierarchy is used to rank the service types. Medical services that overlapped and have different service types are identified and overlapping time is subtracted from the duration of a lower ranked one of the medical services. One or more of the medical services are identified as being billable based on a set of billing rules, and a billing code and a number of billable units are identified for each of the billable medical services.
PURPOSE:To obtain geraniin, by extracting a plant of Aceraceae family with an organic solvent. CONSTITUTION:The dried leaf of a plant of Aceraceae family (e.g. Acer nikoense, Acer buergerianum, Acer saccharum, Acer palmatum, etc.; the stalk and root thereof can be used as well as the leaf) is crushed roughly, mixed with a mixture of acetone and water, and stirred to effect the extraction of the component. The extract is concentrated under reduced pressure, and the obtained liquid is repeatedly extracted with an organic solvent such as ethyl acetate. The extract remaining after the evaporation of the organic solvent in vacuum is subjected e.g. to the combination of the liquid-drop counter-current partition chromatography and the recrystallization from a methanol-water mixture at room temperature, or to the fractionation of the extract by the column chromatography using a polyvinyl resin, etc., to separate geraniin. The compound has astringent action, intestine-controlling action, preventive action to canceration, hypotensive action, etc., is free from the characteristic astringency of tannin and is useful as pharmaceuticals, foods, cosmetics, etc.
Pyrotinib is an oral, irreversible pan-ErbB receptor tyrosine kinase inhibitor (TKI) with activity against epidermal growth factor receptor HER1(EGFR), HER2 and HER4. Improvement of the chemotherapy efficacy and good tolerability have been shown by several stage II and III clinical trials in both the neoadjuvant and metastasis setting in HER2-positive breast cancers. Yet, the anti-tumor effect of Pyrotinib by targeting HER4 has not been determined. Preclinical studies show that HER4 is relatively highly expressed in hormone receptor positive and HER2-negative(HR+/HER2-) breast cancers. In MCF7 cell lines, Pyrotinib effectively repressed phosphorylation of MAPK and Akt signal transduction pathways to inhibit tumor cell proliferation. In HR+/HER2- tumor xenografts, Pyrotinib has been observed to inhibit tumor growth in a dose-dependent manner(unpublished data). Taken together, the data support the rationale that Pyrotinib may be efficacious in HER4 high expressed HR+/HER2- breast cancer and in combination with chemotherapy may lead to a better pCR rate in the neoadjuvant setting.

The study is a two-arm design with a 1:1 allocation ratio (equal numbers of patients randomized to Arms 1, 2,). The sample size will be up to 140 patients with about 70 evaluable patients in each arm. Accrual is expected to occur over 48 months. Patients will be randomized to one of the two neoadjuvant therapy regimens: Patients in Arm 1 will be assigned to receive 400 mg Pyrotinib orally once per day with four cycles of epirubicin (100 mg/m2) (or doxorubicin hydrochloride liposome injection 30mg/m2) and cyclophosphamide (600 mg/m2) intravenously, once every 3 weeks, followed by four cycles of docetaxel (100 mg/m2) intravenously, once every 3 weeks(or nab-paclitaxel 260mg/m2 q3w, or 12 cycles of weekly nab-paclitaxel 120 mg/m2) . Dosage reduction of pyrotinib is permitted from 400 mg to 320 mg or 240 mg if Pyrotinib-related AEs are experienced. In Arm 2 (control), Pyrotinib will be replaced by 400mg placebo provided by the same pharmacy company.

In all arms, clinical response will be evaluated by breast MRI. The primary endpoint will be assessed with the paraffin embedded pathological specimens collected from surgery. Submission of tumor samples for the correlative science studies will be optional for all patients. For patients who agree, pathological sections of core biopsy specimen before treatment (after the patient has signed the consent form and has been screened for eligibility) and pathological sections of surgery residual disease specimen after the completion of the treatment are collected. In addition, a blood sample collected after randomization (before the start of study therapy and after the completion of the neoadjuvant therapy) will also be required for the correlative studies.
OsGADD45a1, a member of the growth arrest and DNA damage-inducible 45 (GADD45) family in rice, has a newly identified homologue, OsGADD45a2, which differs from OsGADD45a1 in only three amino acids. The role and function of the OsGADD45a2 in DNA demethylation are not well-understood and were investigated in this study. Osgadd45a2 mutants exhibited reduced height, shorter panicle length, fewer grains per panicle, and a lower seed setting rate compared with wild-type plants. Moreover, the results showed that OsGADD45a2 negatively regulates rice blast fungus resistance and exhibited high expression in various tissues. Using the 3000 Rice Genomes Project database, we identified four major haplotypes (each with over 100 cultivars) based on single-nucleotide polymorphisms in the coding sequence of OsGADD45a2. Among these, Hap4 was associated with a significantly greater plant height than Hap1-3, possibly due to a functional alteration of OsGADD45a2 linked to the SNP at position 2614993. In OsGADD45a2 overexpression lines, significant decreases in CG and CHG methylation levels were observed in protein-coding genes, leading to their upregulation. Overall, our findings indicate that OsGADD45a2 acts as a methylation regulator, mediating the expression of genes essential for plant growth and development and blast resistance.
Background and Objectives: Left ventricular hypertrophy (LVH) represents a significant cardiovascular risk in patients undergoing chronic hemodialysis (CHD). A large inferior vena cava diameter (IVCD), potentially indicative of fluid overload and a contributing factor to elevated cardiovascular risk, has not been sufficiently explored. Therefore, our study aims to gain further insights into this aspect. Materials and Methods: A retrospective cohort study enrolled patients receiving CHD in a single medical center with available echocardiography from October to December 2018. They were categorized into four groups based on LVH geometry and IVCD. Cox proportional hazard models assessed the risk of major adverse cardiovascular effects (MACEs) and cardiovascular and overall mortality after multivariate adjustments. Kaplan-Meier analysis depicted MACE-free events and survival during the follow-up time. Results: Of the 175 CHD patients, 38, 42, 45, and 50 exhibited small IVCD with eccentric and concentric LVH and large IVCD with eccentric and concentric LVH, respectively. Compared to small IVCD and eccentric LVH, large IVCD and eccentric LVH had the highest risk of MACEs, followed by large IVCD and concentric LVH (aHR: 4.40, 3.60; 95% CI: 1.58-12.23, 1.28-10.12, respectively). As for cardiovascular mortality, large IVCD and concentric LVH had the highest risk, followed by large IVCD and eccentric LVH, and small IVCD and concentric LVH. (aHR: 14.34, 10.23, 8.87; 95% CI: 1.99-103.35, 1.41-74.33; 1.01-77.87). The trend in overall mortality risk among the groups was similar to that of cardiovascular mortality. Conclusions: LVH geometry and IVCD co-modify the risk of MACEs and cardiovascular and overall mortality in CHD patients. The highest risk of MACEs is associated with large IVCD and eccentric LVH, while the highest risk of cardiovascular and overall mortality is linked with large IVCD and concentric LVH.
BACKGROUND: Patients recovering from SARS-CoV-2 infection and acute COVID-19 illness can experience a range of long-term post-acute effects. The potential clinical and economic burden of these outcomes in the USA is unclear. We evaluated diagnoses, medications, healthcare utilization, and medical costs before and after acute COVID-19 illness in US patients who were not at high risk of severe COVID-19.
METHODS: This study included eligible adults who were diagnosed with COVID-19 from April 1 to May 31, 2020, who were 18 - 64 years of age, and enrolled within Optum's de-identified Clinformatics® Data Mart Database for 12 months before and 13 months after COVID-19 diagnosis. Patients with any condition or risk factor placing them at high risk of progression to severe COVID-19 were excluded. Percentages of diagnoses, medications, healthcare utilization, and costs were calculated during baseline (12 months preceding diagnosis) and the post-acute phase (12 months after the 30-day acute phase of COVID-19). Data were stratified into 3 cohorts according to disposition during acute COVID-19 illness (i.e., not hospitalized, hospitalized without intensive care unit [ICU] admission, or admitted to the ICU).
RESULTS: The study included 3792 patients; 56.5% of patients were men, 44% were White, and 94% did not require hospitalization. Compared with baseline, patients during the post-acute phase had percentage increases in the diagnosis of the following disorders: blood (166%), endocrine and metabolic (123%), nervous system (115%), digestive system (76%), and mental and behavioral (75%), along with increases in related prescriptions. Substantial increases in all measures of healthcare utilization were observed among all 3 cohorts. Total medical costs increased by 178% during the post-acute phase. Those who were hospitalized with or without ICU admission during the acute phase had the greatest increases in comorbidities and healthcare resource utilization. However, the burden was apparent across all cohorts.
CONCLUSIONS: As evidenced by resource use in the post-acute phase, COVID-19 places a significant long-term clinical and economic burden among US individuals, even among patients whose acute infection did not merit hospitalization.
FIELD: medicine. SUBSTANCE: method involves administering medicinal preparation with Galavit on the diet background during 5-30 days. It is taken 1-4 times a day before taking meals and in the evening 1.5-2 h after taking meals. Ulcer defect zone is irrigated with Galavit preparation. The Galavit preparation is additionally administered as 1-30 injections. Preparation dose is 25-500 mg in 1-10 ml of water for injections 1-4 times a day. 3-7 days long pause is done after every 5-10 injections. The injections are administered in intramuscular and periulcerous mode. EFFECT: enhanced effectiveness in stimulating immune system; accelerated healing of ulcer defect. 8 cl
Non-pregnant, non-lactating women aged 18+ were recruited by way of posters, to take part in a dietary intervention study that was examining the effects of dietary fat level and fat type on risk factors associated with breast cancer. Women who were normally menstruating, consumed either their habitual diet or a low-fat diet for three menstrual cycles, along with a supplement containing 1.2 g DHA+EPA /day. This was followed by a 3-menstrual cycle washout, where the habitual diet was consumed without a supplement. Subsequently the participants consumed the other diet (either low-fat or habitual) for a further 3 menstrual cycles with the 1.2 g DHA/EPA supplement. Blood, urine and nipple aspirate fluid were collected at the beginning and end of each intervention period and analyzed for a variety of biomarkers. Diet records were collected continuously over the entire study period and periodic 7-day records examined for collection of detailed nutrition information. Anthropometry was completed at each study visit, and nutritional counselling provided throughout.
Congenital lip sinus is a rare entity with upper lip sinus being rarer than the lower lip sinus. It can be an isolated entity or associated with cleft lip, palate or Van der Woude syndrome. Syndromic association requires proper evaluation and aggressive surgical treatment. Preoperative delineation of the sinus tract with ultrasound sonography or MRI is mandatory. Simple excision is sufficient in cases of isolated sinuses. In this article, we report an infant with upper lip sinus managed successfully with simple excision and reviewed the literature.
ACT-ME is designed to reduce behavioral avoidance and to enhance acceptance-based coping. It includes: 1) Behavioral Change Training involving a) teaching patients how to recognize ineffective patterns of behavior and habits, b) exploring and setting life goals and goals related to mental and physical health, and c) promoting effective and committed actions to achieve these goals despite the urge to do otherwise; 2) Acceptance and Mindfulness Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations; and 3) Migraine education whereby each of the educational topics listed below will be covered without detailed discussion of the topics.
Cancer predisposition syndromes are recognized in about 10% of pediatric malignancies with several genes specifically involved in a subset of pediatric tumors such as DICER1, in pleuropulmonary blastoma, cystic nephroma, and brain sarcomas. By contrast, the role of BRCA1/2 in pediatric cancer predisposition is still under investigation. We present two cases of young first-degree cousins, both carrying a germline BRCA2 variant and developing tumors characterized by somatic DICER1 mutations. Patient 1 presented with a cystic nephroma harboring a somatic DICER1 variant (p.Asp1810Tyr), while patient 2 had a primary intracranial DICER1-mutated sarcoma showing a distinct somatic DICER1 variant (p.Asp1709Glu) as well as biallelic inactivation of TP53 (p.Val173Leu, VAF 91%) and APC (p.Ile1307Lys, VAF 95%) and a pathogenic variant in KRAS (p.Gln61His). Both patients carried the same germline BRCA2 variant (p.Arg2842Cys) of unknown significance. The same variant was found in the mother of patient 2 and in the father of patient 1, who are siblings. A homologous recombination deficiency signature was not identified in any of the two tumors, possibly suggesting a reduction of BRCA2 activity. The association of BRCA2 and DICER1 variants in our cases hints at a potential cooperative role in cancer pathogenesis. Further studies are warranted to elucidate the interplay between BRCA1/2 and DICER1 variants and their implications for cancer predisposition and treatment in pediatric patients.